NCT03047213 2026-03-18
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT03097328 2024-04-29
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02091531 2019-11-21
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
Memorial Sloan Kettering Cancer Center
Phase 2 Completed